Coronado Biosciences Inc (NASDAQ:CNDO) shares dipped by 9.11%, Lexicon Pharmaceuticals, Inc (NASDAQ:LXRX)

Posted by Ryan Mandell June 4, 2013 0 Comment 1232 views


Coronado Biosciences Inc (NASDAQ:CNDO): In Monday’s trading session, shares of Coronado Biosciences Inc (NASDAQ:CNDO) dipped by 9.11%. The opening price of the shares was $9.89 which reached an intraday high of $9.94 before dropping to $8.98 per share. In excess of 0.534M shares exchanged hands in the trading session on Monday. This number was higher than the average volume of 0.345M that was measured over 30-day period.

CNDO is a bio-pharma company. It focuses on developing novel immunotherapy biologic agents. These are used for treating cancer and autoimmune diseases. It has two main pharmaceutical product candidates that are in clinical-development. The first is Trichuris suis ova which is a biologic that comprises of microscopic eggs from the porcine whipworm. This is used to treat autoimmune diseases, such as ulcerative colitis, Crohn’s disease and multiple sclerosis. The second drug candidate, CNDO-109, a compound. It activates immune system’s natural killer cells. It seeks and destroys cancer cells. This compound is used to treat acute myeloid leukemia. In 2011 January, Coronado Biosciences Inc (NASDAQ:CNDO) acquired -OvaMed GmbH License.

Lexicon Pharmaceuticals, Inc (NASDAQ:LXRX): In Monday’s trading session, shares of Lexicon Pharmaceuticals, Inc (NASDAQ:LXRX) dipped by 0.21%. The opening price of the shares was $2.40 was also the intraday high, before dropping to $2.38 per share. In excess of 1.97M shares exchanged hands in the trading session on Monday. This number was higher than the average volume of 0.964M that was measured over 30-day period.

Lexicon Pharmaceuticals, Inc (NASDAQ:LXRX) has seen a lot of bullish activity from leading traders. This is in most probability in direct response to LX4211, its lead product. This product is being considered by some speculators as a best-in-class, SGLT inhibitor. The potential cardiovascular benefits, infection risk and renal safety efficacy that it offers, is above that of other existing SGLT inhibitors. In effect, LX4211 is being considered by some, to be a topper in the SGLT bunch. In 2013, Lexicon Pharmaceuticals, Inc (NASDAQ:LXRX)’s Year-To-Date gains are what the company’s stock created last Thursday. The stock has traded around 7% higher. The reason for this dismal performance has been the lack of catalysts right through the year.


About Ryan Mandell

Ryan Mandell is our senior staff writer covering the White House for Political Report, Ryan also coordinates with the main newsroom news items and contributing write-ups on cultural, social and political activities. Ryan holds an undergraduate degree in journalism, a Doctorate in international relations and a Master Degree in mass communications with an emphasis in print journalism. Ryan also covered the International Society of Social Defense congress in Spain in 2007 and taken part in the Global Forum on economic policies

View all post by Ryan Mandell Visit author's website

Write Your Comment